Table 1.
Participants characteristics at Sister Study enrollment
| Premenopausal at enrollment | Postmenopausal at enrollment | |||
|---|---|---|---|---|
| Breast cancer (n=296) | No breast cancer (n=394) | Breast cancer (N=517) | No breast cancer (N=655) | |
| N(%)a | N(%)a | N(%)a | N(%)a | |
| Age (years), mean (SD) | 47.6 (5.0) | 46.6 (5.1) | 59.2 (5.1) | 58.3 (5.4) |
| Race/ethnicity | ||||
| Non-Hispanic white | 269 (91) | 333 (85) | 467 (91) | 584 (89) |
| Non-Hispanic black | 12 (4) | 36 (9) | 23 (4) | 36 (6) |
| Hispanic | 8 (3) | 20 (5) | 14 (3) | 24 (4) |
| Other | 7 (2) | 5 (1) | 12 (2) | 11 (2) |
| Education | ||||
| High school or less | 30 (10) | 44 (11) | 61 (12) | 98 (15) |
| Some college | 74 (25) | 123 (31) | 158 (31) | 205 (31) |
| Bachelor’s degree or higher | 192 (65) | 227 (58) | 297 (58) | 352 (54) |
| Household income | ||||
| Less than $50,000 | 33 (11) | 59 (15) | 95 (19) | 150 (24) |
| $50,000 to $99,999 | 113 (39) | 170 (44) | 219 (44) | 255 (40) |
| $100,000 or more | 143 (49) | 158 (41) | 183 (37) | 229 (36) |
| Smoking status | ||||
| Never | 184 (62) | 241 (61) | 268 (52) | 348 (53) |
| Former | 99 (33) | 120 (30) | 216 (42) | 263 (40) |
| Current | 13 (4) | 33 (8) | 33 (6) | 44 (7) |
| Ever diagnosed with diabetes | ||||
| Yes | 5 (2) | 11 (3) | 24 (5) | 56 (9) |
| No | 287 (97) | 373 (95) | 472 (91) | 579 (88) |
| Borderline | 4 (1) | 10 (3) | 21 (4) | 20 (3) |
| Ever diagnosed with hypertension | ||||
| Yes | 33 (11) | 46 (12) | 152 (29) | 180 (27) |
| No | 254 (86) | 338 (86) | 336 (65) | 437 (67) |
| Borderline | 9 (3) | 10 (3) | 29 (6) | 38 (6) |
| Ever diagnosed with high cholesterol | ||||
| Yes | 59 (20) | 72 (18) | 200 (39) | 258 (39) |
| No | 204 (69) | 277 (70) | 241 (47) | 315 (48) |
| Borderline | 33 (11) | 45 (11) | 75 (15) | 81 (12) |
| Age at breast cancer diagnosis, mean (SD) | 51.6 (5.3) | 62.9 (5.2) | ||
| Stage | ||||
| 0 | 75 (25) | 123 (24) | ||
| II | 135 (46) | 270 (52) | ||
| II | 67 (23) | 108 (21) | ||
| III | 19 (6) | 13 (3) | ||
| Treatment | ||||
| No chemotherapy, no endocrine therapy | 49 (17) | 85 (17) | ||
| Chemotherapy, no endocrine therapy | 37 (13) | 44 (9) | ||
| Endocrine therapy, no chemotherapy | 120 (41) | 264 (52) | ||
| Chemotherapy and endocrine therapy | 88 (30) | 115 (23) | ||
a Numbers may not sum to total due to missing